Parabilis Medicines (PBLS) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Viking Therapeutics is the larger company by market cap ($3.63 billion vs $3.39 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PBLS | VKTX |
|---|---|---|
| Share price | $27.48 | $28.51 |
| Market cap | $3.39B | $3.63B |
| 1-day change | -2.17% | +2.81% |
| YTD return | — | -18.96% |
| 1-year return | — | -18.50% |
| 5-year return | — | +374.38% |
| EPS (TTM) | $-9.51 | $-4.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Net income (latest FY) | — | $-359.64M |
| 52-week high | $42.49 | $43.15 |
| 52-week low | $24.51 | $25.77 |
| Distance from 52-week high | -35.33% | -33.93% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +51.93% | +232.20% |
| Average volume | 690.91K | 4.13M |
| Shares outstanding | 121.95M | 127.17M |
| Employees | 145 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Parabilis Medicines
PBLS stock →Parabilis Medicines, Inc. operates as a clinical-stage biopharmaceutical company focused on developing helical peptide therapeutics for disease treatment.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
PBLS vs VKTX FAQ
Which is bigger, Parabilis Medicines or Viking Therapeutics?
Viking Therapeutics (VKTX) is larger, with a market capitalization of $3.63B compared with $3.39B for Parabilis Medicines (PBLS).
Are Parabilis Medicines and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.